Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer

Translational Oncology

Volumn 5, Issue 4, 2012, Pages 278-287

  Ewald, Jonathan A ^a   Jarrard, David F ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIAZIQUONE; S PHASE KINASE ASSOCIATED PROTEIN 2;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL AGING; CELL PROLIFERATION; CELL VIABILITY; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; THERAPY INDUCED SENESCENCE; TREATMENT DURATION; TUMOR XENOGRAFT;

EID: 84865478942     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12181     Document Type: Article

References (55)

1. Ben-Porath I and Weinberg RA (2004). When cells get stressed: an integrative view of cellular senescence. J Clin Invest 113, 8-13.
2. Campisi J (2001). Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 11, S27-S31.
3. Campisi J and d'Adda di Fagagna F (2007). Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8, 729-740.
4. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92, 9363-9367.
5. d'Adda di Fagagna F (2008). Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8, 512-522.
6. Lawless C, Wang C, Jurk D, Merz A, Zglinicki TV, and Passos JF (2010). Quantitative assessment of markers for cell senescence. Exp Gerontol 45, 772-778.
7. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, and Blagosklonny MV (2009). Pseudo-DNA damage response in senescent cells. Cell Cycle 8, 4112-4118.
8. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, and Campisi J (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853-2868.
9. Chang BD, Swift ME, Shen M, Fang J, Broude EV, and Roninson IB (2002). Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci USA 99, 389-394.
10. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, and Jarrard DF (2002). Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 277, 14877-14883.
11. Bringold F and Serrano M (2000). Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 35, 317-329.
12. wafl/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808-4818.
13. Ewald JA, Desotelle JA, Wilding G, and Jarrard DF (2010). Therapy-induced senescence in cancer. J Natl Cancer Inst 102, 1536-1546.
14. Roninson IB (2003). Tumor cell senescence in cancer treatment. Cancer Res 63, 2705-2715.
15. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, and Roninson IB (1999). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59, 3761-3767.
16. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, and Jarrard DF (2005). The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 7, 816-823.
17. Roberson RS, Kussick SJ, Vallieres E, Chen SY, and Wu DY (2005). Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 65, 2795-2803.
18. te Poele RH, Okorokov AL, Jardine L, Cummings J, and Joel SP (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62, 1876-1883.
19. Di X, Bright AT, Bellott R, Gaskins E, Robert J, Holt S, Gewirtz D, and Elmore L (2008). A chemotherapy-associated senescence bystander effect in breast cancer cells. Cancer Biol Ther 7, 864-872.
20. Ewald JA, Desotelle JA, Almassi N, and Jarrard DF (2008). Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 98, 1244-1249.
21. INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346.
22. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, and Lowe SW (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
23. Haugstetter AM, Loddenkemper C, Lenze D, Grone J, Standfuss C, Petersen I, Dorken B, and Schmitt CA (2010). Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 103, 505-509.
24. Ewald JA, Peters N, Desotelle JA, Hoffmann FM, and Jarrard DF (2009). A high-throughput method to identify novel senescence-inducing compounds. J Biomol Screen 14, 853-858.
25. Bender JF, Grillo-Lopez AJ, and Posada JG Jr (1983). Diaziquone (AZQ). Invest New Drugs 1, 71-84.
26. Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146-155.
27. Frescas D and Pagano M (2008). Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer 8, 438-449.
28. Hershko DD (2008). Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 112, 1415-1424.
29. KIP1: androgen regulation and prognostic significance in prostate cancer. Adv Clin Path 4, 226-232.
30. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, and Loda M (2001). Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15, 765-782.
31. Gao D, Inuzuka H, Tseng A, and Wei W (2009). Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/ Cdhl. Cell Div 4, 11.
32. Majumder PK and Sellers WR (2005). Akt-regulated pathways in prostate cancer. Oncogene 24, 7465-7474.
33. Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, et al. (2009). Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol 11, 420-432.
34. kip1. J Pathol 218, 419-427.
35. Kip1. Int J Oncol 34, 1425-1431.
36. Ewald JA, Wilkinson JC, Guyer CA, and Staros JV (2003). Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp Cell Res 282, 121-131.
37. Passaniti A, Adler SH, and Martin GR (1992). New models to define factors determining the growth and spread of human prostate cancer. Exp Gerontol 27, 559-566.
38. Schwarze SR, Shi Y, Fu VX, Watson PA, and Jarrard DF (2001). Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20, 8184-8192.
39. Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J, and Jarrard DF (2004). A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J Biol Chem 279, 52218-52226.
40. Liliensiek SJ, Schell K, Howard E, Nealey P, and Murphy CJ (2006). Cell sorting but not serum starvation is effective for SV40 human corneal epithelial cell cycle synchronization. Exp Eye Res 83, 61-68.
41. Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, et al. (1999). p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res 59, 2957-2964.
42. Campisi J (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522.
43. Ben-Porath I and Weinberg RA (2005). The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 37, 961-976.
44. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, et al. (2010). A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 120, 681-693.
45. Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG, and Hyer ML (2010). MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 8, 373-384.
46. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379.
47. Chu IM, Hengst L, and Slingerland JM (2008). The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8, 253-267.
48. KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90, 1284-1291.
49. Hershko DD (2010). Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target. Future Oncol 6, 1837-1847.
50. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. (1995). Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip 1 in human malignancies. Cancer Res 55, 2266-2269.
51. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55, 1211-1214.
52. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjo S, Murga M, et al. (2010). Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 12, 54-59, sup pp. 51-14.
53. KIP1 through SKP2 in human leukemia cells. J Biol Chem 286, 9815-9825.
54. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, and Nakayama KI (2004). Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 6, 1229-1235.
55. Kip1 stability and cell migration under metabolic stress. Cell Cycle 10, 2592-2602.